In this episode of the Big Biz Show, our CEO, Christian Kanstrup, delves into the details of the recently announced partnership for vaccine development with MSD, which expands the companies’ existing collaboration and brings significant value to Evaxion.

Advancing Vaccine Development through Precise AI-driven Prediction of Protective Antigens.

CEO Christian Kanstrup joined Steve Darling from Proactive to announce the launch of an enhanced version of the company’s clinically validated AI‑Immunology™ platform, featuring an updated EDEN AI prediction model.

Last week, our CEO, Christian Kanstrup, joined the Life Sciences Investor Forum to present Evaxion's clinically validated AI-Immunology™ platform, highlighting our extensive pipeline of novel vaccine candidates in cancer and infectious diseases and discussing our strategic approach to partnerships.

In this webinar, key opinion leader and the trial’s principal investigator, Professor Georgina V. Long, will present the data from the one-year interim analysis and discuss challenges in the medical treatment of advanced melanoma.

In this interview, Bob "Sully" Sullivan and Mike Costa from the Big Biz Show interview our CEO, Christian Kanstrup, about Evaxion's Innovative AI-Immnuology™ platform, personalized cancer vaccines, and market projections.

Phase 2 study of AI-designed personalized neoantigen cancer vaccine, EVX-01, in combination with pembrolizumab in advanced melanoma

Are you eager to deep-dive into Evaxion's business? Download our company presentation.

Publication: Nature Communications
Authors: Asolina Braun, Louise C. Rowntree, Ziyi Huang, Kirti Pandey, Nikolas Thuesen, Chen Li, Jan Petersen, Dene R. Littler, Shabana Raji, Thi H. O. Nguyen, Emma Jappe Lange, Gry Persson, Michael Schantz Klausen, Jens Kringelum, Shanzou Chung, Nathan P. Croft, Pouya Faridi, Rochelle Ayala, Jamie Rossjohn, Patricia T. Illing, Katherine E. Scull, Sri Ramarathinam, Nicole A. Mifsud, Katherine Kedzierska, Anders Bundgård Sørensen & Anthony W. Purcell

Publication: Springer Protocols
Authors: Nikolas Thuesen and Michael Schantz Klausen

In this interview, Bob "Sully" Sullivan and Mike Costa from the Big Biz Show interview our CEO, Christian Kanstrup, about Evaxion's Innovative AI-Immnuology™ platform, personalized cancer vaccines, and market projections.

Immunogenicity of an AI-designed personalized neoantigen vaccine, EVX-01, in combination with anti-PD1 therapy in patients with metastatic melanoma